Amplify Treatments Testing and Advancements -$0.03 -0.16% Friday 18:54
1D 1W 1M 3M 1Y 5Y
1.86 % Dividend Yield
This list is based on the watchlists of people on Stock Events who follow GERM. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna, Inc. focuses on mRNA-based therapies, directly competing in the biotech space for treatments and vaccines, similar to GERM's focus on advanced treatments. BioNTech
BNTX
Mkt Cap 20.98B
BioNTech SE specializes in personalized immunotherapies, which overlaps with GERM's advancements in treatment technologies.
Pfizer Inc. has a broad portfolio in healthcare, including treatments and vaccines that compete with GERM's product offerings.
Novavax, Inc. is involved in the development of vaccines, competing in the same space as GERM's focus on treatment and prevention. Gilead Sciences
GILD
Mkt Cap 98.35B
Gilead Sciences, Inc. is known for its antiviral drugs, directly competing with GERM's advancements in treatments. Regeneron Pharmaceuticals
REGN
Mkt Cap 130.59B
Regeneron Pharmaceuticals, Inc. works on biopharmaceuticals, including treatments that could rival GERM's innovative therapies.
AbbVie Inc. operates in the pharmaceuticals sector, with a focus on advanced therapies that could compete with GERM's product line. Johnson & Johnson
JNJ
Mkt Cap 399.26B
Johnson & Johnson has a diverse healthcare portfolio, including pharmaceuticals that could compete with GERM's treatments.
Amgen Inc. focuses on human therapeutics, which could compete with GERM's advancements in treatment technologies. Astrazeneca
AZN
Mkt Cap 271.67B
AstraZeneca PLC has a wide range of pharmaceutical products, including treatments and vaccines that could compete with GERM's offerings. Miscellaneous
Investment Trusts/Mutual Funds
The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund invests at least 80% of its total assets in the component securities of the index. The fund is non-diversified.
Show more...